Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Maze Therapeutics, Inc.NASDAQ: MAZE
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $23.68M (cash outflow) rose 1561.5% year over year, ahead of the +605.7% change in trailing-twelve-month change in working capital. Sequentially, it rose 7512.9% from the prior quarter. Over 3 fiscal years it compounded at -11.1% a year.
Context
- Change in working capital grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1561.5% holds above the trailing-twelve-month pace of +605.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (2.27M) USD
- Year-over-year change
- -49.2%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.27M) | -49.2% |
| FY2024 | 2024-12-31 | (1.52M) | +75.9% |
| FY2023 | 2023-12-31 | (6.32M) | -95.2% |
| FY2022 | 2022-12-31 | (3.24M) | — |
Change in Working Capital vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +605.7% is the 2nd highest of 8, against a peer median of -31.7%.
- Change in working capital amounts to 112.8% of revenue for MAZE, versus a peer median of 8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $94.28M USD | +1496.3% | -17.5% | 9.3% | |
| LTM Sep 2026 | $52.67M USD | +188.9% | — | 8.1% | |
| LTM Mar 2026 | $28.23M USD | -31.7% | +17.0% | 6.6% | |
| LTM Mar 2026 | $22.56M USD | +605.7% | -11.1% | 112.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $10.29M USD | -223.3% | — | 99.7% |
SEPNSepterna, Inc. | LTM Sep 2026 | $6.99M USD | -104.2% | +353.4% | 7.3% |
| FY2025 | €6.42M EUR | +282.2% | +4.0% | 143.1% | |
| LTM Mar 2026 | $1.07M USD | -65.7% | +4.9% | — | |
| Peer median (excluding MAZE) | — | -31.7% | +4.9% | 8.7% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.